Chavan Sandip, Majumdar Ramanath, Joshi Neha, Madden Benjamin, Peterson Jane, Tauscher Craig T, Schieber Jennifer E, Norgan Andrew P, Jacob Eapen K, Pandey Akhilesh, Juskewitch Justin E
Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Manipal Academy of Higher Education, Manipal, Karnataka, India.
Transfusion. 2025 May;65(5):968-977. doi: 10.1111/trf.18252. Epub 2025 Apr 16.
Tandem mass spectrometry (MS/MS) has become a common clinical laboratory testing modality has demonstrated success in distinguishing between small protein variations in transthyretin amyloidosis. Since many common clinically significant RBC antigens are also small protein variations, this study aimed to determine if MS/MS could correctly detect common RBC antigens within the Rh, Kell, Duffy, MNS, Kidd, Diego, and Lutheran blood group systems.
Residual samples from serotyped/genotyped blood donors at a hospital-based blood donation center from February to August 2021 were analyzed. RBC membrane protein preparations underwent protease digestion prior to MS/MS analysis for RhD, RhCE, Kell, atypical chemokine receptor 1 (Duffy), glycophorin A (MNS), glycophorin B (MNS), urea transporter 1 (Kidd), band 3 anion transport protein (Diego), and basal cell adhesion molecule (Lutheran). Untargeted liquid chromatography (LC)-MS/MS detected protein-specific peptides, while targeted LC-selected reaction monitoring (LC-SRM) detected RBC antigen-containing peptides.
Through the use of multiple proteases, untargeted LC-MS/MS detected protein-specific peptides in all but glycophorin B, with band 3 anion transport protein, basal cell adhesion molecule, Kell, and glycophorin A having the greatest protein sequence coverage. Targeted LC-SRM detected antigen-specific peptides for C, Di/Di, Kp, and Wr/Wr, which agreed with the donors' previous typing results.
MS/MS can successfully detect peptides from several blood group systems but only detected a subset of their common RBC antigens. Further sample enrichment and MS/MS detection improvements will need to occur before MS/MS could be considered a clinical RBC phenotyping modality.
串联质谱(MS/MS)已成为临床实验室常用的检测方法,在区分转甲状腺素蛋白淀粉样变性中的小蛋白变异方面已取得成功。由于许多临床上重要的常见红细胞抗原也是小蛋白变异,本研究旨在确定MS/MS能否正确检测Rh、Kell、Duffy、MNS、Kidd、Diego和Lutheran血型系统中的常见红细胞抗原。
对2021年2月至8月某医院献血中心血清分型/基因分型献血者的剩余样本进行分析。在进行MS/MS分析之前,对红细胞膜蛋白制剂进行蛋白酶消化,以检测RhD、RhCE、Kell、非典型趋化因子受体1(Duffy)、血型糖蛋白A(MNS)、血型糖蛋白B(MNS)、尿素转运蛋白1(Kidd)、带3阴离子转运蛋白(Diego)和基底细胞粘附分子(Lutheran)。非靶向液相色谱(LC)-MS/MS检测蛋白质特异性肽段,而靶向LC-选择反应监测(LC-SRM)检测含红细胞抗原的肽段。
通过使用多种蛋白酶,非靶向LC-MS/MS除血型糖蛋白B外,在所有样本中均检测到蛋白质特异性肽段,带3阴离子转运蛋白、基底细胞粘附分子、Kell和血型糖蛋白A的蛋白质序列覆盖率最高。靶向LC-SRM检测到C、Di/Di、Kp和Wr/Wr的抗原特异性肽段,与献血者先前的分型结果一致。
MS/MS可以成功检测来自多个血型系统的肽段,但仅检测到其常见红细胞抗原的一个子集。在MS/MS被认为是一种临床红细胞表型分析方法之前,还需要进一步进行样本富集和MS/MS检测改进。